Riskpilot← Back to searchSign inGet full accessABIGO PHARMA A/S
A/SDissolvedCVR 12927983Gydevang 33Specialiseret engroshandel med fødevarer i.a.n. · NACE 463890Est. 19891 employees
Revenue 2023
DKK 9,2M
-29% vs 2022
EBITDA margin
1.2%
-57% vs 2022
Equity ratio
80.9%
Financial strength
Net profit 2023
DKK 202K
+22% vs 2022
| Revenue | DKK 9,2M | -29% |
| EBITDA | DKK 113K | -57% |
| Net profit | DKK 202K | +22% |
| Total assets | DKK 6M | -7% |
| Equity | DKK 4,8M | +4% |
| Employees | 1 | — |
Legal name
ABIGO PHARMA A/S
CVR number
12927983
Legal form
Aktieselskab
NACE code
463890 · Specialiseret engroshandel med fødevarer i.a.n.
Founded
1. marts 1989
Share capital
DKK 500.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening.
Address
Gydevang 33
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.729 | 2.686 | 2.772 | 3.522 | 5.766 | 5.326 | 3.677 | 5.740 | 5.794 | 6.205 | 12.898 | 12.886 | 9.189 |
| Staff expenses | -2.256 | -2.314 | -2.321 | -3.314 | -4.774 | -5.038 | -3.237 | -5.900 | -5.843 | -5.907 | -6.852 | -3.207 | -983 |
| EBITDA | 472 | 371 | 451 | 208 | 992 | 288 | 440 | -160 | -49 | 298 | 6.046 | 265 | 113 |
| Depreciation & amort. | 149 | 17 | -17 | -4 | -2 | -2 | -6 | -0 | -7 | -16 | -16 | -5 | -0 |
| EBIT | 323 | 355 | 435 | 204 | 991 | 286 | 434 | -160 | -55 | 282 | 6.030 | 260 | 113 |
| Net financials | -271 | -222 | -195 | -164 | -148 | -105 | -68 | -127 | -120 | -77 | -91 | -44 | 147 |
| Profit before tax | 52 | 132 | 240 | 40 | 842 | 181 | 367 | -193 | -175 | 205 | 5.940 | 216 | 260 |
| Tax | 29 | 48 | 149 | 39 | 200 | 42 | 92 | 47 | -29 | 50 | 1.310 | 50 | 59 |
| Net profit | 23 | 85 | 91 | 1 | 642 | 138 | 275 | -240 | -146 | 155 | 4.630 | 166 | 202 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6.588 | 5.543 | 5.933 | 7.787 | 5.657 | 6.134 | 6.324 | 5.670 | 6.454 | 6.800 | 7.957 | 6.450 | 5.983 |
| Equity | -1.159 | -1.075 | -984 | -983 | -341 | -203 | 72 | -168 | -314 | -159 | 4.471 | 4.637 | 4.839 |
| Long-term debt | 4.243 | 3.324 | 3.051 | 4.031 | 2.173 | 1.500 | 1.500 | 1.500 | 1.690 | 2.052 | 0 | 0 | 0 |
| Short-term debt | 3.504 | 3.294 | 3.866 | 4.739 | 3.825 | 4.837 | 4.752 | 4.338 | 5.078 | 4.907 | 3.444 | 1.804 | 1.108 |
| Total debt | 7.747 | 6.618 | 6.917 | 8.770 | 5.998 | 6.337 | 6.252 | 5.838 | 6.768 | 6.959 | 3.444 | 1.804 | 1.108 |
EBITDA margin
1.2%
This company
15.8%
Market median
-92% vs market
20122023
Equity ratio
80.9%
This company
38.2%
Market median
+112% vs market
20122023
Return on equity
4.2%
This company
18.4%
Market median
-77% vs market
20122023
Net profit margin
2.2%
This company
8.1%
Market median
-73% vs market
20122023
Asset turnover
1.54×
This company
1.12×
Market median
+37% vs market
20122023
Debt / equity
0.24×
This company
0.62×
Market median
+61% vs market
20122023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-05-01 – 2017-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
- Annual report 2012Filed via CVR / Virk · Period 2011-05-01 – 2012-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FÅ Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
BD Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
ET | Audit | 1989 | — | — |
HE Management | Management | 1989 | — | — |
CD Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
PN Deputy | Deputy | 2015 | — | — |
FD Management | Management | 1989 | — | — |
HJ Chief Executive Officer | Chief Executive Officer | 2003 | — | — |
EJ Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
FR Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
CM | Deputy | 2015 | — | — |
PE Management | Management | 1989 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1989 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 1989 | — | — | |
| Board of Directors | 1989 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 1989 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 1989 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Essity Denmark A/S | Company | 100.0% | 100.0% | 2023 |
| Individual | 66.7% | 66.7% | 2020 | |
| Individual | 100.0% | 100.0% | 2021 | |
| Individual | 25.0% | 25.0% | 1989 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ABIGO PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Frank Åke Joakim Jehlbo | Chief Executive Officer | 0 companies |
| Bjarne Dennis Reffeldt Otte | Chief Executive Officer | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Henry Erik Mikkelsen | Management | 0 companies |
| Claes Dahl | Chief Executive Officer | 0 companies |
| Per-Oluf Nilsson | Deputy | 0 companies |
| Finn Dyrby Hermansen | Management | 0 companies |
| Henrik Jensen | Chief Executive Officer | 0 companies |
| Erik Johan Brobjer | Chief Executive Officer | 0 companies |
| Fredrik Ralph Stenbäcker | Chief Executive Officer | 0 companies |
| Carl Magnus Anders Elliot | Deputy | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Jørgen Sandstrøm Lindeberg | Board of Directors | 0 companies |
| Artur Bernardino Aira | Board of Directors | 0 companies |
| Leif Smith | Board of Directors | 0 companies |
| Arne Paalberg | Board of Directors | 0 companies |
| Christina Maria Rydebrink | Board of Directors | 0 companies |
| Wentzel Bohn-Willeberg | Chairman | 0 companies |
| Johan Lindberg | Chairman | 0 companies |
| Jan Smith | Board of Directors | 0 companies |
| Ulrika Wictoria Wilson | Chairman | 0 companies |
| Susanne Saul Stakemann | Board of Directors | 0 companies |